BR9810186A - Diabetes treatment with thiazolidinedione and alpha-glycosity inhibitor - Google Patents

Diabetes treatment with thiazolidinedione and alpha-glycosity inhibitor

Info

Publication number
BR9810186A
BR9810186A BR9810186-2A BR9810186A BR9810186A BR 9810186 A BR9810186 A BR 9810186A BR 9810186 A BR9810186 A BR 9810186A BR 9810186 A BR9810186 A BR 9810186A
Authority
BR
Brazil
Prior art keywords
alpha
inhibitor
glycosity
thiazolidinedione
diabetes treatment
Prior art date
Application number
BR9810186-2A
Other languages
Portuguese (pt)
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712865.6A external-priority patent/GB9712865D0/en
Priority claimed from GBGB9806708.5A external-priority patent/GB9806708D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of BR9810186A publication Critical patent/BR9810186A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"TRATAMENTO DE DIABETE COM TIAZOLIDINADIONA E INIBIDOR DE ALFA-GLICOSIDASE" Descreve-se um método para o tratamento de diabete melito e condições associadas a diabete melito em um mamífero, método esse que compreende administrar uma quantidade eficaz, atóxica e farmaceuticamente aceitável de um sensibilizador de insulina, e um agente anti-hiperglicêmico inibidor de alfa-glicosidase, a um mamífero que dela necessite."TREATMENT OF DIABETES WITH THIAZOLIDINADION AND ALPHA-GLYCOSIDASE INHIBITOR" A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal is described, a method which comprises administering an effective, non-toxic and pharmaceutically acceptable amount of a sensitizer insulin, and an anti-hyperglycemic alpha-glucosidase inhibitor, to a mammal that needs it.

BR9810186-2A 1997-06-18 1998-06-15 Diabetes treatment with thiazolidinedione and alpha-glycosity inhibitor BR9810186A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9712865.6A GB9712865D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806708.5A GB9806708D0 (en) 1998-03-27 1998-03-27 Novel method
PCT/EP1998/003691 WO1998057635A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor

Publications (1)

Publication Number Publication Date
BR9810186A true BR9810186A (en) 2000-08-08

Family

ID=26311746

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9810186-2A BR9810186A (en) 1997-06-18 1998-06-15 Diabetes treatment with thiazolidinedione and alpha-glycosity inhibitor

Country Status (24)

Country Link
EP (1) EP0975343A1 (en)
JP (1) JP2001523271A (en)
KR (1) KR20010013845A (en)
CN (1) CN1274282A (en)
AP (1) AP9901720A0 (en)
AR (2) AR014881A1 (en)
AU (1) AU8799998A (en)
BG (1) BG103966A (en)
BR (1) BR9810186A (en)
CA (1) CA2294134A1 (en)
CO (1) CO4940453A1 (en)
DZ (1) DZ2519A1 (en)
EA (1) EA200000040A1 (en)
IL (1) IL133138A0 (en)
MA (1) MA26510A1 (en)
NO (1) NO996270L (en)
NZ (1) NZ501345A (en)
OA (1) OA11631A (en)
PE (1) PE89199A1 (en)
PL (1) PL337577A1 (en)
SK (1) SK179499A3 (en)
TR (1) TR199903072T2 (en)
UY (1) UY25051A1 (en)
WO (1) WO1998057635A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0009934A (en) 1999-04-23 2002-06-04 Smithkline Beecham Plc Pharmaceutical
CN100384430C (en) 2001-04-04 2008-04-30 奥索-麦克尼尔药品公司 Combination therepy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
CA2442917C (en) 2001-04-04 2011-02-01 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
FR2832930A1 (en) * 2001-12-03 2003-06-06 Lipha PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-GLUCOSIDASE INHIBITOR AND A THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF FOR THE PREPARATION OF MEDICINES FOR TREATING DIABETES
JP2004067575A (en) * 2002-08-06 2004-03-04 Yaizu Suisankagaku Industry Co Ltd Promoter for effect of therapeutic agent for diabetes
CN101121004B (en) * 2006-08-08 2010-07-21 鲁南制药集团股份有限公司 Medicine composition containing insulin intensifier and miglitol
CN101584688B (en) * 2008-05-24 2010-11-10 鲁南制药集团股份有限公司 Medicament composition for treating diabetes and complications of diabetes
CN101584705B (en) * 2008-05-24 2010-10-27 鲁南制药集团股份有限公司 Medicament composition for treating diabetes and complications of diabetes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900435A (en) * 1991-08-26 1999-05-04 Pharmacia & Upjohn Company Composition, food product and uses of 3-guanidinopropionic acid
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
AR013352A1 (en) 2000-12-27
WO1998057635A1 (en) 1998-12-23
AP9901720A0 (en) 1999-12-31
UY25051A1 (en) 2000-09-29
JP2001523271A (en) 2001-11-20
KR20010013845A (en) 2001-02-26
AU8799998A (en) 1999-01-04
MA26510A1 (en) 2004-12-20
TR199903072T2 (en) 2000-07-21
OA11631A (en) 2004-11-22
AR014881A1 (en) 2001-04-11
PE89199A1 (en) 1999-10-23
IL133138A0 (en) 2001-03-19
BG103966A (en) 2000-07-31
CO4940453A1 (en) 2000-07-24
PL337577A1 (en) 2000-08-28
EA200000040A1 (en) 2000-08-28
SK179499A3 (en) 2000-11-07
NO996270D0 (en) 1999-12-17
DZ2519A1 (en) 2003-02-01
NO996270L (en) 1999-12-17
NZ501345A (en) 2001-10-26
CN1274282A (en) 2000-11-22
EP0975343A1 (en) 2000-02-02
CA2294134A1 (en) 1998-12-23

Similar Documents

Publication Publication Date Title
BR9810172A (en) Treatment of diabetes with thiazolidinedione and metformin
BR9911656A (en) Pharmaceutical composition, processes for the prevention or treatment of diabetes in a mammal, for the prevention or treatment of diabetic complications in a mammal and for the prevention or treatment of impaired glucose tolerance in a mammal, use of an insulin sensitizer, and, process to reduce the side effects of an insulin sensitizer or / and an anoretic administered to a diabetic mammal
ES2187659T3 (en) TREATMENT OF TYPE II MELLITUS DIABETES WITH AMILINA AGONISTS.
BR0111800A (en) Depeptidyl peptidase iv inhibitor combinations and other antidiabetic agents for the treatment of diabetes mellitus
BR0109553A (en) Method for the improvement of islet signaling in diabetes mellitus and its prevention
BR9810445A (en) Diabetes treatment with thiazolidinedione, insulin secretagogue and diguanide
UY24893A1 (en) GLITAZONE SULFONYLUREA COMBINATIONS FOR DIABETES
KR950002785A (en) Parathyroid hormone and raloxyphene to increase bone mass
BR9810444A (en) Treatment of diabetes with rosiglitazone and insulin
EA200100541A1 (en) PHARMACEUTICAL COMPOSITION WITH MODIFIED SURVIVAL OF THE SENSITIZER TO INSULIN AND OTHER ANTI-DIABETIC AGENTS
BR9106977A (en) METHOD TO SUPPRESS AUTOIMMUNE DESTRUCTION OF PANCREATIC BETA CELUIAS, PHARMACEUTICAL FORMULATION, PROPHYLAXIS METHOD, METHOD TO PREVENT THE SURGE OF TYPE 1 DIABETES AND METHOD FOR TREATING A MAMMAL
EA200101089A1 (en) NEW METHOD OF TREATMENT
BR9810186A (en) Diabetes treatment with thiazolidinedione and alpha-glycosity inhibitor
NO20083276L (en) Treatment of diabetes with thiazolidinedione and sulfonylurea
BR9810292A (en) Diabetes treatment with thiazolidinedione, insulin secretagogue and alpha-glucosidase inhibitor
KR900007424A (en) Method of using N-acetylglucosamine as a cytoprotective agent and composition thereof
HUP0104388A2 (en) Combinations comprising a betha-agonist and a further antidiabetic agent
MY138246A (en) Treatment of diabetes with thiazolidione and sulphonylurea.
BR9809376A (en) Pregnan-3-ol-20-ones
BR9815220A (en) Use of thiazolidinediones for the treatment of hyperglycemia
BR9815219A (en) Use of thiazolidinediones for the treatment of hyperglycemia
NO980556L (en) Procedure for reducing the amount of exogenous insulin administered to a patient with non-insulin-dependent diabetes mellitus
ECSP982541A (en) NEW METHOD OF TREATMENT II
ECSP982535A (en) NEW TREATMENT METHOD (I)
ECSP982593A (en) NEW METHOD OF TREATMENT VI

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A,7A,8A E 9AANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1909 DE 07/08/2007.